熱門資訊> 正文
GeneDx任命Linda Genen博士为CMO
2026-01-06 21:48
- GeneDx (NASDAQ:WGS) on Tuesday stated the appointment of Linda Genen, MD, MPH, as Chief Medical Officer.
- Genen brings decades of leadership across clinical care, payer strategy, innovation, and maternal-infant health, joining the company from ProgenyHealth, where she served as CMO following a career as a neonatologist and healthcare executive.
- At UnitedHealth Group and Optum, Genen served in senior leadership roles, driving the development and scaling of innovative care models in women’s health, digital health, and maternal-infant medicine.
- Presently, she is a board member at Hera Women’s Health and a distinguished mentor in Stanford University’s Clinical Informatics management program.
More on GeneDx Holdings Corp.
- GeneDx Holdings Corp. (WGS) Q3 2025 Earnings Call Transcript
- GeneDx Holdings Corp. 2025 Q3 - Results - Earnings Call Presentation
- GeneDx: A Moment Of Reckoning As Market Awaits Q3 Testing Growth
- GeneDx raises 2025 revenue guidance to $428M amid accelerating exome and genome test growth
- GeneDx Holdings Corp. Q3 2025 Earnings Preview
推薦文章
港股周報 | 中國大模型「春節檔」打響！智譜周漲超138%；鉅虧超230億！美團周內重挫超10%
一周財經日曆 | 港美股迎「春節+總統日」雙假期！萬億零售巨頭沃爾瑪將發財報
一周IPO | 賺錢效應持續火熱！年內24只上市新股「0」破發；「圖模融合第一股」海致科技首日飆漲逾242%
從軟件到房地產，美國多板塊陷入AI恐慌拋售潮
Meta計劃為智能眼鏡添加人臉識別技術
危機四伏，市場卻似乎毫不在意
美股機會日報 | 降息預期升溫！美國1月CPI年率創去年5月來新低；淨利、指引雙超預期！應用材料盤前漲超10%
財報前瞻 | 英偉達Q4財報放榜在即！高盛、瑞銀預計將大超預期，兩大關鍵催化將帶來意外驚喜？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
